← Back to your selection

Catalio Capital Management

Activity from announced rounds

Activity in this selectionUnited States · Oct 15, 2026 · Jul 18, 2026
Rounds participated in
4
Confirmed lead rounds
1
1 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$245M
4 disclosed · full round size, not this investor’s share

By stage

Series B2
Series C+2

By primary sector

Biotech3
Healthtech1

By country

United States4

Rounds

4 in this selection
BigHat Biosciences

An AI and synthetic-biology platform that designs and engineers antibody therapeutics.

$75MSeries C
Participant
Evvy

Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health.

$40MSeries B
Lead
Superluminal Medicines

Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

$60MSeries B
Participant
Ratio Therapeutics

Developing best-in-class radiopharmaceuticals for cancer treatment

$70MSeries C
Role not disclosed